Infinity Extends R&D Collaboration With Mundipharma, Gets Another $50 Million For PI3K Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.
You may also be interested in...
Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.
Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.
Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.